Trials / Completed
CompletedNCT06109831
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic
An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 335 (actual)
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1918 | SHR-1918 |
| DRUG | SHR-1918 placebo | SHR-1918 placebo |
Timeline
- Start date
- 2023-11-24
- Primary completion
- 2025-07-04
- Completion
- 2025-07-04
- First posted
- 2023-10-31
- Last updated
- 2026-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06109831. Inclusion in this directory is not an endorsement.